Table 1.
Clinical and pathology characteristics for the entire cohort and for the endometrioid tumors only.
| Characteristic | All Endometrial Cancer (n = 342) |
Endometrioid Histology (n = 245) |
Mixed Endometrioid & Non-Endometrioid Histology (n = 50) |
Non-Endometrioid Histology (n = 47) |
|---|---|---|---|---|
|
| ||||
| Age in years, mean (SD) | 60.6 (11.7) | 59.2 (11.7) | 63.1 (10.3) | 65.3 (12.1) |
|
| ||||
| Body mass index in kg/m2, mean (SD)a | 33.8 (10.5) | 35.0 (10.7) | 32.6 (9.5) | 28.9 (8.8) |
|
| ||||
| Race, n (%) | ||||
| White | 245 (72%) | 174 (71%) | 36 (72%) | 35 (74%) |
| Black | 28 (8%) | 12 (5%) | 8 (16%) | 8 (17%) |
| Hispanic | 54 (16%) | 47 (19%) | 4 (8%) | 3 (6%) |
| Asian | 14 (4%) | 11 (5%) | 2 (4%) | 1 (2%) |
| Other | 1 (0%) | 1 (0%) | 0 (0%) | 0 (0%) |
|
| ||||
| Histology, n (%) | ||||
| Endometrioid | 245 (72%) | N/A | N/A | N/A |
| Mixed Endometrioid and Non-Endometrioid | 50 (15%) | |||
| Non-Endometrioid | 47 (14%) | |||
|
| ||||
| Grade for pure endometrioid tumors, n (%)b | ||||
| 1 | N/A | 30 (13%) | N/A | N/A |
| 2 | 161 (67%) | |||
| 3 | 48 (20%) | |||
|
| ||||
| Myometrial invasion, n (%)c | ||||
| < 50% | 183 (58%) | 141 (60%) | 25 (57%) | 17 (44%) |
| ≥ 50% | 134 (42%) | 93 (40%) | 19 (43%) | 22 (56%) |
|
| ||||
| LVSI, n (%)d | ||||
| No | 138 (45%) | 116 (50%) | 13 (32%) | 9 (24%) |
| Yes | 170 (55%) | 114 (50%) | 28 (68%) | 28 (76%) |
|
| ||||
| Tumor size in cm, mean (SD)e | 4.8 (3.2) | 4.5 (3.2) | 5.2 (2.9) | 6.2 (3.6) |
|
| ||||
| Stage, n (%)f | ||||
| I or II | 210 (63%) | 173 (72%) | 24 (49%) | 13 (28%) |
| III or IV | 126 (38%) | 68 (28%) | 25 (51%) | 33 (72%) |
|
| ||||
| Mutations, n (%) | ||||
| PTEN | 154 (45%) | 132 (54%) | 17 (34%) | 5 (11%) |
| PIK3CA | 135 (39%) | 101 (41%) | 22 (44%) | 12 (26%) |
| ARID1Ag | 86 (38%) | 68 (42%) | 13 (36%) | 5 (19%) |
| PIK3R1g | 53 (24%) | 43 (27%) | 9 (25%) | 1 (4%) |
| TP53 | 73 (21%) | 32 (13%) | 19 (38%) | 22 (47%) |
| KRAS | 66 (19%) | 52 (21%) | 9 (18%) | 5 (11%) |
| CTNNB1 | 60 (18%) | 53 (22%) | 6 (12%) | 1 (2%) |
| FGFR2 | 32 (9%) | 28 (11%) | 4 (8%) | 0 (0%) |
340 patients were included in BMI assessment for the overall cohort; 2 patients did not have either a height or weight recorded at the time of their initial evaluation at the University of Texas MD Anderson Cancer Center.
239 patients were included in the endometrioid grade assessment; 6 received neoadjuvant chemotherapy.
317 patients were included in the myometrial invasion assessment for the overall cohort; 16 received neoadjuvant, 9 did not have information available.
308 patients were included in the LVSI assessment for the overall cohort; 16 received neoadjuvant chemotherapy, 18 patients did not have information available.
300 patients were included in the tumor size assessment for the overall cohort; 16 received neoadjuvant chemotherapy, 26 did not have accurate tumor size information available.
336 patients were included in the stage assessment for the overall cohort; 6 patients did not have clinical, pathology, or radiological information available for stage assessment.
225 patients were included in the analyses for the overall cohort for both ARID1A and PIK3R1.